These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 29427543)
1. FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. Lin J; Ji A; Qiu G; Feng H; Li J; Li S; Zou Y; Cui Y; Song C; He H; Lu Y Cancer Sci; 2018 Apr; 109(4):1001-1011. PubMed ID: 29427543 [TBL] [Abstract][Full Text] [Related]
2. Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. Wang Q; Qian J; Wang J; Luo C; Chen J; Hu G; Lu Y J Neurooncol; 2013 Mar; 112(1):73-82. PubMed ID: 23292182 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014 [TBL] [Abstract][Full Text] [Related]
4. Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1. Zhu Y; Wang H; Fei M; Tang T; Niu W; Zhang L Mol Neurobiol; 2021 Apr; 58(4):1438-1452. PubMed ID: 33190170 [TBL] [Abstract][Full Text] [Related]
5. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells. Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809 [TBL] [Abstract][Full Text] [Related]
6. Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray. Lin J; Zuo J; Cui Y; Song C; Wu X; Feng H; Li J; Li S; Xu Q; Wei W; Qiu G; He H Oncol Rep; 2018 May; 39(5):2333-2341. PubMed ID: 29565460 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma. Xu JX; Yang Y; Zhang X; Luan XP Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1922-1931. PubMed ID: 32141561 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells. Zhou B; Bu G; Zhou Y; Zhao Y; Li W; Li M Med Oncol; 2015 Jan; 32(1):378. PubMed ID: 25433945 [TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
11. Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest. Wang P; Ye JA; Hou CX; Zhou D; Zhan SQ Oncol Rep; 2016 Nov; 36(5):2544-2552. PubMed ID: 27633132 [TBL] [Abstract][Full Text] [Related]
12. EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest. Yu Q; Liu L; Wang P; Yao Y; Xue Y; Liu Y Cell Cycle; 2017 Jun; 16(11):1085-1092. PubMed ID: 28436750 [TBL] [Abstract][Full Text] [Related]
13. Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. Filippi-Chiela EC; Thomé MP; Bueno e Silva MM; Pelegrini AL; Ledur PF; Garicochea B; Zamin LL; Lenz G BMC Cancer; 2013 Mar; 13():147. PubMed ID: 23522185 [TBL] [Abstract][Full Text] [Related]
14. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721 [TBL] [Abstract][Full Text] [Related]
16. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Montaldi AP; Godoy PR; Sakamoto-Hojo ET Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369 [TBL] [Abstract][Full Text] [Related]
17. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells. Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389 [TBL] [Abstract][Full Text] [Related]
18. Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment. Chen Y; Gao F; Jiang R; Liu H; Hou J; Yi Y; Kang L; Liu X; Li Y; Yang M J Cell Biochem; 2017 Dec; 118(12):4905-4913. PubMed ID: 28569417 [TBL] [Abstract][Full Text] [Related]
19. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967 [TBL] [Abstract][Full Text] [Related]
20. MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment. He H; Yao M; Zhang W; Tao B; Liu F; Li S; Dong Y; Zhang C; Meng Y; Li Y; Hu G; Luo C; Zong H; Lu Y Cell Mol Immunol; 2016 Sep; 13(5):658-68. PubMed ID: 26189368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]